Design, Synthesis, and In Vitro Antimicrobial Evaluation of a Novel Tetrahydro-[3,4'-bipyrazole]-1-carbaldehyde Derivative

The rapid escalation of multidrug-resistant bacterial and fungal pathogens represents a profound threat to clinical medicine worldwide. In the quest for novel pharmacophores capable of circumventing established resistance mechanisms, pyrazole-based heterocycles have emerged as privileged structural frameworks. In this study, we report the design, synthesis, structural characterization, and in vitro antimicrobial assessment of a novel clubbed bis-pyrazole entity: 1'-(4-chlorophenyl)-3'-methyl-5'-oxo-5-phenyl-4,4',5,5'-tetrahydro-1H,1'H-[3,4'-bipyrazole]-1-carbaldehyde. The target compound was successfully synthesized via a multi-step condensation approach and structurally verified using FTIR, 1H-NMR, 13C-NMR, and elemental analysis. In vitro antimicrobial screening was executed using the agar-well diffusion method and microdilution assays against standard bacterial strains (Staphylococcus aureus, S.Pyogenus, Escherichia coli, Pseudomonas aeruginosa) and fungal pathogens (Candida albicans, Aspergillus niger). The compound displayed promising antimicrobial efficacy, highlighted by a notable zone of inhibition and low Minimum Inhibitory Concentration (MIC) values. These findings underscore the potential of combining halogenated phenyl groups with a formylated bipyrazole core to create highly active, narrow-to-broad-spectrum antimicrobial agents